Previous 10 | Next 10 |
– Preclinical data in ASD model demonstrate prosocial effects of MM-402 – Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates t...
Research into psychedelics has increased significantly in the recent years, as we learn more about their beneficial properties. Before the psychedelic renaissance, trials on the effectiveness of psilocybin were conducted in the 1960s. However, research grinded to a halt following the classifica...
– Over 50% of patients dosed across 20 active clinical sites – – On Track for Topline Results in late 2023 – Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopha...
Legislators in Vermont recently discussed a bill to legalize psilocybin and begin offering regulated access to the drug. The state of Vermont is one of many states where legislators have shown interest in advancing psychedelic reform. The bill in question, H. 371 , was sponsored by Representativ...
FCM Believes MindMed Focused on Pursuing Misguided Clinical Path for MM-120 MindMed Executives, Advisors – Barrow, Karlin, and Liechti – Do Not Have Experience in Bringing Drugs to Market and Are Making Fundamental Errors in Approach MindMed Cash Expected to Run Ou...
2023-05-05 17:29:03 ET Mind Medicine (MindMed) Inc. (MNMD) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Rob Barrow – Chief Executive Officer Schond Greenway – Chief Financial Officer Dan Karlin – Chief Medical ...
Clerkenwell Health , a psychedelic-specialist clinical research firm, recently partnered with MYndspan, which will give medical researchers access to magnetoencephalography (MEG) scanners. MYndspan is a brain analytics firm that allows users to evaluate and monitor brain health to extend the he...
2023-05-05 11:16:50 ET Mind Medicine press release ( NASDAQ: MNMD ): Q1 GAAP EPS of -$0.65 misses by $0.22 . As of March 31, 2023, MindMed had cash and cash equivalents totaling $129.4 million compared to $142.1 million as of December 31, 2022. The Company believes its...
MindMed Board has Presided over Botched Regulatory Strategies, Outsized Expenses, Soaring Executive Compensation, and Value Destructive Financings FCM’s Four Highly Qualified Director Nominees to Bring Desperately Needed Accountability, Expertise, and Fresh Shareholder Focused Pe...
– Key MM-120 readouts in GAD (Phase 2b) and ADHD (Phase 2a) expected by end of 2023 – – MM-402 pre-clinical data in ASD model to be presented at ASCP 2023 Annual Meeting – – Strengthened leadership team with appointment of Mark R. Sullivan as...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...
Cluster headaches are headaches characterized by severe pain that often occurs on a side of the head or behind one eye. These headaches may last anywhere between 15 minutes to 3 hours and usually strike suddenly, often recurring more than once a day. The pain experienced by patients is... R...